Explore the Global Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market — Key Trends, Regional Growth, Top Players, and 10-Year Forecast from 2026 to 2036

Future Market Insights

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

Key Insight

Anti-fibrotic medication will lead progressive fibrosing interstitial lung disease (PF-ILD) treatment sales through 2036 with 47.0% of the drug type segment in 2026. The market was valued at USD 5.35 billion in 2025 and is expected to reach USD 10.2 billion by 2036, creating an incremental opportunity of USD 4.48 billion.

April 28, 2026

Anurag Sharma

298 Pages

Cite this Report

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

https://www.futuremarketinsights.com/reports/progressive-fibrosing-interstitial-lung-disease-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Blade Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
FibroGen Inc
Galapagos NV
Kiniksa Pharmaceuticals
Pliant Therapeutics
Roche
Samumed
Verona Pharma Plc

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

Key Players

Similar Industry Reports